p63 Antibody

Tumor protein 63, p63, Chronic ulcerative stomatitis protein, CUSP, Keratinocyte transcription factor KET, Transformation-related protein 63, TP63, Tumor protein p73-like, p73L, p40, p51, TP63, KET, P63, P73H, P73L, TP73L

Flow Cytometry: 0.5-1 ug/million cells in 0.1ml

Immunofluorescence: 1-2 ug/ml

Immunohistochemistry (FFPE): 1-2 ug/ml for 30 minutes at RT

The optimal dilution of the p63 antibody for each application should be determined by the researcher.

p63 is a homolog of the tumor suppressor p53. It is identified in basal cells in the epithelial layers of a variety of tissues, including epidermis, cervix, urothelium, breast and prostate. p63 was detected in nuclei of the basal epithelium in normal prostate glands; however, it was not expressed in malignant tumors of the prostate. As a result, p63 has been reported as a useful marker for differentiating benign from malignant lesions in the prostate, particularly when used in combination with markers of high molecular weight cytokeratins and the prostate-specific marker AMACR (P504S). p63 has also been shown to be a sensitive marker for lung squamous cell carcinomas (SqCC), with a sensitivity of ~90%. Specificity for lung SqCC, vs. lung adenocarcinoma (LADC), is approximately 80%. In breast tissue, p63 has been identified in myoepithelial cells of normal ducts.

PBS with 0.1 mg/ml BSA and 0.05% sodium azide

0.2 mg/mL

Unconjugated

Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.

Recombinant partial human p53 protein was used as the immunogen for this p63 antibody.

8626

tumor protein p63

TP63

Homo sapiens

Liquid

Protein A affinity chromatography

Cancer,Cell Cycle,Signal Transduction

Q9H3D4

Optimal dilutions for each application to be determined by the researcher